PortalPublikationenSystemic chemotherapy of pediatric recurrent ependymomas: re...

Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies

Standard

Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. / Adolph, Jonas E; Fleischhack, Gudrun; Gaab, Christine; Mikasch, Ruth; Mynarek, Martin; Rutkowski, Stefan; Schüller, Ulrich; Pfister, Stefan M; Pajtler, Kristian W; Milde, Till; Witt, Olaf; Bison, Brigitte; Warmuth-Metz, Monika; Kortmann, Rolf-Dieter; Dietzsch, Stefan; Pietsch, Torsten; Timmermann, Beate; Tippelt, Stephan; German GPOH HIT-Network.

in: J NEURO-ONCOL, Jahrgang 155, Nr. 2, 11.2021, S. 193-202.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Adolph, JE, Fleischhack, G, Gaab, C, Mikasch, R, Mynarek, M, Rutkowski, S, Schüller, U, Pfister, SM, Pajtler, KW, Milde, T, Witt, O, Bison, B, Warmuth-Metz, M, Kortmann, R-D, Dietzsch, S, Pietsch, T, Timmermann, B, Tippelt, S & German GPOH HIT-Network 2021, 'Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies', J NEURO-ONCOL, Jg. 155, Nr. 2, S. 193-202. https://doi.org/10.1007/s11060-021-03867-8

APA

Adolph, J. E., Fleischhack, G., Gaab, C., Mikasch, R., Mynarek, M., Rutkowski, S., Schüller, U., Pfister, S. M., Pajtler, K. W., Milde, T., Witt, O., Bison, B., Warmuth-Metz, M., Kortmann, R-D., Dietzsch, S., Pietsch, T., Timmermann, B., Tippelt, S., & German GPOH HIT-Network (2021). Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. J NEURO-ONCOL, 155(2), 193-202. https://doi.org/10.1007/s11060-021-03867-8

Vancouver

Adolph JE, Fleischhack G, Gaab C, Mikasch R, Mynarek M, Rutkowski S et al. Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. J NEURO-ONCOL. 2021 Nov;155(2):193-202. https://doi.org/10.1007/s11060-021-03867-8

Bibtex

@article{a7a5496813ae43d2b355421c60af7109,
title = "Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies",
abstract = "PURPOSE: Survival in recurrent ependymoma (EPN) depends mainly on the extent of resection achieved. When complete resection is not feasible, chemotherapy is often used to extend progression-free and overall survival. However, no consistent effect of chemotherapy on survival has been found in patients with recurrent EPN.METHODS: Systemic chemotherapeutic treatment of 138 patients enrolled in the German HIT-REZ-studies was analyzed. Survival depending on the use of chemotherapy, disease-stabilization rates (RR), duration of response (DOR) and time to progression (TTP) were estimated.RESULTS: Median age at first recurrence was 7.6 years (IQR: 4.0-13.6). At first recurrence, median PFS and OS were 15.3 (CI 13.3-20.0) and 36.9 months (CI 29.7-53.4), respectively. The Hazard Ratio for the use of chemotherapy in local recurrences in a time-dependent Cox-regression analysis was 0.99 (CI 0.74-1.33). Evaluable responses for 140 applied chemotherapies were analyzed, of which sirolimus showed the best RR (50%) and longest median TTP [11.51 (CI 3.98; 14.0) months] in nine patients, with the strongest impact found when sirolimus was used as a monotherapy. Seven patients with progression-free survival > 12 months after subtotal/no-resection facilitated by chemotherapy were found. No definitive survival advantage for any drug in a specific molecularly defined EPN type was found.CONCLUSION: No survival advantage for the general use of chemotherapy in recurrent EPN was found. In cases with incomplete resection, chemotherapy was able to extend survival in individual cases. Sirolimus showed the best RR, DOR and TTP out of all drugs analyzed and may warrant further investigation.",
author = "Adolph, {Jonas E} and Gudrun Fleischhack and Christine Gaab and Ruth Mikasch and Martin Mynarek and Stefan Rutkowski and Ulrich Sch{\"u}ller and Pfister, {Stefan M} and Pajtler, {Kristian W} and Till Milde and Olaf Witt and Brigitte Bison and Monika Warmuth-Metz and Rolf-Dieter Kortmann and Stefan Dietzsch and Torsten Pietsch and Beate Timmermann and Stephan Tippelt and {German GPOH HIT-Network}",
note = "{\textcopyright} 2021. The Author(s).",
year = "2021",
month = nov,
doi = "10.1007/s11060-021-03867-8",
language = "English",
volume = "155",
pages = "193--202",
journal = "J NEURO-ONCOL",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

RIS

TY - JOUR

T1 - Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies

AU - Adolph, Jonas E

AU - Fleischhack, Gudrun

AU - Gaab, Christine

AU - Mikasch, Ruth

AU - Mynarek, Martin

AU - Rutkowski, Stefan

AU - Schüller, Ulrich

AU - Pfister, Stefan M

AU - Pajtler, Kristian W

AU - Milde, Till

AU - Witt, Olaf

AU - Bison, Brigitte

AU - Warmuth-Metz, Monika

AU - Kortmann, Rolf-Dieter

AU - Dietzsch, Stefan

AU - Pietsch, Torsten

AU - Timmermann, Beate

AU - Tippelt, Stephan

AU - German GPOH HIT-Network

N1 - © 2021. The Author(s).

PY - 2021/11

Y1 - 2021/11

N2 - PURPOSE: Survival in recurrent ependymoma (EPN) depends mainly on the extent of resection achieved. When complete resection is not feasible, chemotherapy is often used to extend progression-free and overall survival. However, no consistent effect of chemotherapy on survival has been found in patients with recurrent EPN.METHODS: Systemic chemotherapeutic treatment of 138 patients enrolled in the German HIT-REZ-studies was analyzed. Survival depending on the use of chemotherapy, disease-stabilization rates (RR), duration of response (DOR) and time to progression (TTP) were estimated.RESULTS: Median age at first recurrence was 7.6 years (IQR: 4.0-13.6). At first recurrence, median PFS and OS were 15.3 (CI 13.3-20.0) and 36.9 months (CI 29.7-53.4), respectively. The Hazard Ratio for the use of chemotherapy in local recurrences in a time-dependent Cox-regression analysis was 0.99 (CI 0.74-1.33). Evaluable responses for 140 applied chemotherapies were analyzed, of which sirolimus showed the best RR (50%) and longest median TTP [11.51 (CI 3.98; 14.0) months] in nine patients, with the strongest impact found when sirolimus was used as a monotherapy. Seven patients with progression-free survival > 12 months after subtotal/no-resection facilitated by chemotherapy were found. No definitive survival advantage for any drug in a specific molecularly defined EPN type was found.CONCLUSION: No survival advantage for the general use of chemotherapy in recurrent EPN was found. In cases with incomplete resection, chemotherapy was able to extend survival in individual cases. Sirolimus showed the best RR, DOR and TTP out of all drugs analyzed and may warrant further investigation.

AB - PURPOSE: Survival in recurrent ependymoma (EPN) depends mainly on the extent of resection achieved. When complete resection is not feasible, chemotherapy is often used to extend progression-free and overall survival. However, no consistent effect of chemotherapy on survival has been found in patients with recurrent EPN.METHODS: Systemic chemotherapeutic treatment of 138 patients enrolled in the German HIT-REZ-studies was analyzed. Survival depending on the use of chemotherapy, disease-stabilization rates (RR), duration of response (DOR) and time to progression (TTP) were estimated.RESULTS: Median age at first recurrence was 7.6 years (IQR: 4.0-13.6). At first recurrence, median PFS and OS were 15.3 (CI 13.3-20.0) and 36.9 months (CI 29.7-53.4), respectively. The Hazard Ratio for the use of chemotherapy in local recurrences in a time-dependent Cox-regression analysis was 0.99 (CI 0.74-1.33). Evaluable responses for 140 applied chemotherapies were analyzed, of which sirolimus showed the best RR (50%) and longest median TTP [11.51 (CI 3.98; 14.0) months] in nine patients, with the strongest impact found when sirolimus was used as a monotherapy. Seven patients with progression-free survival > 12 months after subtotal/no-resection facilitated by chemotherapy were found. No definitive survival advantage for any drug in a specific molecularly defined EPN type was found.CONCLUSION: No survival advantage for the general use of chemotherapy in recurrent EPN was found. In cases with incomplete resection, chemotherapy was able to extend survival in individual cases. Sirolimus showed the best RR, DOR and TTP out of all drugs analyzed and may warrant further investigation.

U2 - 10.1007/s11060-021-03867-8

DO - 10.1007/s11060-021-03867-8

M3 - SCORING: Journal article

C2 - 34657224

VL - 155

SP - 193

EP - 202

JO - J NEURO-ONCOL

JF - J NEURO-ONCOL

SN - 0167-594X

IS - 2

ER -